Jefferies upgraded Vertex to Buy from Hold following improved fundamentals and a growing pipeline worth $5 billion-7 billion, which includes treatments for chronic pain and APOL1 kidney disease.

It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have lost about 8.6% in that time frame, underperforming the S&P 500. Will the recent negative ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...

Chair of Vertex’s TDT Program Steering Committee, and Presenting Author of the CASGEVY clinical data at ASH. “With median follow-up around three years there is strong evidence for the ...

ABU DHABI, UNITED ARAB EMIRATES - OCTOBER 21: Islam Makhachev of Russia prepares to face Alexander ... [+] Volkanovski of Australia in the UFC lightweight championship fight during the UFC 294 ...

The first UFC pay-per-view card on the 2025 schedule, UFC 311, has its main event. In that contest, UFC lightweight champion Islam Makhachev puts his title on the line against Arman Tsarukyan in a ...

Taking place at the Intuit Dome in Los Angeles, California, UFC 311 will be headlined by a lightweight title bout between Islam Makhachev and #1-ranked lightweight contender Arman Tsarukyan in a ...